A 28-year-old man with HIV/AIDS (CD4 count 45 cells/µL) presents with a 5-day history of painful vesicular lesions on the genitals and perirectal area. Viral culture and PCR confirm herpes simplex virus type 2 (HSV-2). He is currently on antiretroviral therapy. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context This patient has severe immunosuppression (CD4 < 50 cells/µL) with confirmed HSV-2 infection. At this CD4 nadir, HSV disease carries high risk of dissemination, atypical presentation, and treatment failure with oral antivirals alone. ## Why IV Acyclovir Is Correct **Key Point:** In patients with CD4 count < 50 cells/µL, HSV infection should be treated with IV acyclovir (not oral) due to high risk of: - Disseminated disease (esophagitis, hepatitis, encephalitis, retinitis) - Poor oral bioavailability in severe immunosuppression - Acyclovir-resistant HSV (especially with prior prolonged oral exposure) **High-Yield:** Standard IV acyclovir dosing for HSV in severe immunosuppression is 10–15 mg/kg IV every 8 hours. Adequate renal function assessment is essential (risk of crystalline nephropathy). **Clinical Pearl:** Disseminated HSV in advanced AIDS can present with: - Hemorrhagic esophagitis - Hepatitis with transaminitis - Meningoencephalitis - Retinitis (rare, more common with CMV) - Chronic perirectal ulcers (may be massive) ## Management Algorithm for HSV in Advanced AIDS ```mermaid flowchart TD A[Confirmed HSV Infection]:::outcome --> B{CD4 Count?}:::decision B -->|> 200 cells/µL| C[Oral Acyclovir/Valacyclovir]:::action B -->|< 50 cells/µL| D[IV Acyclovir 10-15 mg/kg Q8H]:::action D --> E{Assess for dissemination}:::decision E -->|Localized| F[Continue IV acyclovir]:::action E -->|Disseminated/Severe| G[IV acyclovir + evaluate for complications]:::action C --> H[Monitor response]:::action F --> I[Immune reconstitution with ART]:::action G --> I ``` **Table: HSV Treatment by CD4 Count** | CD4 Count | Presentation | First-line | Route | Dose | | --- | --- | --- | --- | --- | | > 200 cells/µL | Localized HSV | Acyclovir/Valacyclovir | Oral | 400–800 mg 5× daily | | 50–200 cells/µL | Localized or atypical | IV Acyclovir | IV | 10–15 mg/kg Q8H | | < 50 cells/µL | Any HSV (high dissemination risk) | IV Acyclovir | IV | 10–15 mg/kg Q8H | | < 50 cells/µL | Acyclovir-resistant HSV | Foscarnet or Cidofovir | IV | Per protocol | ## Why Other Options Are Incorrect **Oral acyclovir 400 mg five times daily** is inadequate in CD4 < 50 cells/µL due to poor absorption, high dissemination risk, and potential for resistant HSV emergence. Oral therapy is appropriate only for CD4 > 200 cells/µL. **Oral valacyclovir**, despite better bioavailability than acyclovir, is still not sufficient for CD4 < 50 cells/µL. IV therapy is mandatory to ensure adequate CNS and visceral penetration and prevent disseminated disease. **Topical acyclovir ointment** has negligible systemic absorption and is ineffective for systemic HSV disease in severe immunosuppression. Monotherapy with topical agents risks dissemination and treatment failure.